Sanofi expects first dengue vaccine license in Q4

After Sanofi's ($SNY) sizable investment into its dengue vaccine program, new company CEO Olivier Brandicourt said on the Q3 call that the French pharma expects its first license to market the vaccine by year end, FiercePharmaAsia reported. A "first wave of launches" is expected for next year, he added. Sanofi's vaccines head, Olivier Charmeil, said that the company doesn't know whether it'll have sales this quarter for the jab. "What you should keep in mind, should we get sales, it's going to be very, very minimal, but we are expecting to get licensed for dengue this quarter," Charmeil said. Sanofi has spent 20 years and $1.5 billion to develop the vaccine, which India's Economic Times reported this week will be a focus for Sanofi in that country, along with 5 other drugs it plans to bring to market there. FiercePharmaAsia story | More from The Economic Times

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.